Abstract
A series of novel substituted 5-phenyl-methyl (Z)-2-(1-amino-2-((1,3,4-oxadiazol-2-yl)thio)ethylidene)hydrazine-1-carboxylate scaffolds 4(a-m) have been synthesized to assess their potential as anti-inflammatory and anticancer agents. The structures of the synthesized derivatives were established by employing 1H- NMR, 13C- NMR, and LC-MS analysis. In particular, thirteen derivatives were evaluated for their in vivo anti-inflammatory activity by making use of carrageenan-induced paw edema in SD rats and in vitro anticancer activity towards the BT474 female breast cancer cell line. Among the tested derivatives, Compound 4f emerged as a key lead and showed significant inhibition in paw edema volume in vivo (81 %), and compound 4e exhibited interesting ability to inhibit cellular proliferation in vitro (IC50=3.78 µM for BT474) compared to Doxorubicin (IC50 = 6.795 μM). Based on the structure-activity relationship, the presence of electron-donating substituents along with oxadiazole nucleus seems favorable for biological activities. A docking study was performed to understand the molecular interactions of the synthesized compounds which revealed that the compounds perfectly docked into the active sites of the protein.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.